Magnetic resonance imaging (MRI) has revealed isolated pituitary stalk thickening (PST) in certain cases of idiopathic or secondary central diabetes insipidus (DI) due to infiltrative processes. Twenty-six children with DI and PST underwent cerebral MRI at the age of 8 ± 4 years and were followed (n = 25) by clinical and MRI evaluation for 5.5 ± 3.6 and 3.0 ± 2 years, respectively, but given no treatment other than hormonal substitutive therapy. Patients were subdivided into groups according to the etiology of the DI: germinoma (n = 4), Langerhans’ histiocytosis (n = 5) or ‘idiopathic’ DI with PST (n = 17). Complete anterior pituitary evaluation in 24 of the 26 patients revealed that 14 children were suffering from associated growth hormone deficiency and 7 had multiple hormone deficiencies. At the first MRI evaluation, pituitary stalk enlargement varied from 2.2 to 9.0 mm. The anterior pituitary gland was found to be normal (n = 12), small (n = 8) or enlarged (n = 6). At the final evaluation, a change in MRI features had occurred in 16 patients: morphological and/or signal changes in the PST (n = 16; 6 of whom showed an increase in PST) and changes in anterior pituitary gland size (n = 8; 3 of whom had increased and 5 had decreased). The presence of a growing suprasellar mass with a progressively enlarging pituitary stalk was demonstrated in the 6 patients who had shown increased pituitary stalk enlargement 1.8 ± 1.6 years after the first MRI. In 4 of these patients, a diagnosis of germinoma was made 1.3 ± 0.6 years after PST identification by MRI at the onset of DI, but the other 2 patients showing a suprasellar mass were still categorized as ‘idiopathic’ at the final clinical evaluation performed 7.8 and 12.3 years after DI onset. In 10 patients (all but 1 with Langerhans’ histiocytosis, showing ‘idiopathic’ DI) the pituitary stalk enlargement was diminished after 2.0 ± 1.9 years of MRI follow-up, and there was a complete reversal of pituitary stalk enlargement in 5 patients. We conclude that the natural history of ‘idiopathic’ isolated central DI with PST is unpredictable. Although germinoma should always be considered during the first 3 years of follow-up in patients presenting isolated DI with PST by repeated investigations every 3–6 months, it remains an infrequent etiology, affecting only 15% of cases in our study.

Keywords:
Diabetes insipidus, Tumor, Germinoma, Histiocytosis
1.
Fujisawa I, Nishimura K, Asato R, Tageshi K, Itoh K, Noma S, Kawamura Y, Sago T, Minami S, Nakano Y, Itoh H, Torizuka K: Posterior lobe of the pituitary in diabetes insipidus: MR findings. J Comput Assist Tomogr 1987;11:221–225.
2.
Tien R, Kucharczyk J, Kucharczyk W: MR imaging of the brain in patients with diabetes insipidus. Am J Neuroradiol 1991;12:533–542.
3.
Maghnie M, Villa A, Arico M, Larizza D, Pezzotta S, Beluffi G, Genovese E, Severi F: Correlation between magnetic resonance imaging of posterior pituitary and neurohypophyseal function in children with diabetes insipidus. J Clin Endocrinol Metab 1992;74:795–800.
4.
Imura H, Nakao K, Shimatsu A, Ogawa Y, Sando T, Fujisawa I, Yamabe H: Lymphocytic infundibuloneurohypophysitis as a cause of central diabetes insipidus. N Engl J Med 1993;329:683–689.
5.
Ahmed R, Aiello DP, Page R, Hopper K, Towfighi J, Santen RJ: Necrotizing infundibulo-hypophysitis: A unique syndrome of diabetes insipidus and hypopituitarism. J Clin Endocrinol Metab 1993;76:1499–1504.
6.
Banerjee A, Leger J, Garel C, Hassan M, Czernichow P: Anomalies morphologiques de la tige pituitaire sans cause reconnue dans quatre cas de diabète insipide de l’enfant. Arch Pédiatr 1994;1:233–240.
7.
Mootha SL, Barkovich AJ, Grumbach MH, Edwards MS, Gitelman SE, Kaplan SL, Conte FA: Idiopathic hypothalamic diabetes insipidus, pituitary stalk thickening and the occult intracranial germinoma in children and adolescents. J Clin Endocrinol Metab 1997;82:1362–1367.
8.
Léger J, Velasquez A, Garel C, Hassan M, Czernichow P: Thickened pituitary stalk on magnetic resonance imaging in children with central diabetes insipidus. J Clin Endocrinol Metab 1999;84:1954–1960.
9.
Dunger DB, Broadbent V, Yeoman E, Sekl JR, Lightman SL, Grant DB, Pritchard J: The frequency and natural history of diabetes insipidus in children with Langerhans’ cell histiocytosis. N Engl J Med 1989;321:1157–1162.
10.
Kilpatrick SE, Wenger DE, Gilchrist GS, Shives TC, Wollan PC: Langerhans’ cell histiocytosis of bone. Cancer 1995;76:2471–2484.
11.
Egeler RM, D’Angio GJ: Langerhans’ cell histiocytosis. J Pediatr 1995;127:1–11.
12.
Grois N, Flucher-Wolfram B, Heitger A, Mostbeck GH, Hofmann J, Gadner H: Diabetes insipidus in Langerhans’ cell histiocytosis: Results from the DAL-HX 83 study. Med Pediatr Oncol 1995;24:248–256.
13.
Broadbent V, Pritchard J, Davies EG, Levinsky RJ, Heaf D, Atherton DJ, Pincott JR, Tucker S: Spontaneous remission of multisystem histiocytosis X. Lancet 1984;i:253–254.
14.
Broadbent V, Dunger DB, Yeomans E, Kendall B: Anterior pituitary function and computed tomography/magnetic resonance imaging in patients with Langerhans’ cell histiocytosis and diabetes insipidus. Med Pediatr Oncol 1993;21:649–654.
15.
Fujisawa K, Asato R, Okumura R, Nakano Y, Shibata T, Hamanaka D, Hashimoto T, Konishi J: Magnetic resonance imaging of neurohypophyseal germinomas. Cancer 1991;68:1009–1014.
16.
Pomarede R, Czernichow P, Finidori J, Roger M, Kalifa C, Zucker JM, Pierre-Kahn A, Rappaport R: Endocrine aspects and tumoral markers in intracranial germinoma: An attempt to delineate the diagnostic procedure in 14 patients. J Pediatr 1982;101:374–378.
17.
Sklar CA, Grumbach MM, Kaplan SL, Conte FA: Hormonal and metabolic abnormalities associated with central nervous system germinoma in children and adolescents and the effect of therapy: Report of 10 patients. J Clin Endocrinol Metab 1981;52:9–16.
18.
Scherbaum WA, Bottazzo G: Autoantibodies to vasopressin cells in idiopathic diabetes insipidus: Evidence for an autoimmune variant. Lancet 1983;i:897–899.
19.
Scherbaum WA, Czernichow P, Bottazo GF, Doniach D: Diabetes insipidus in children. A possible autoimmune type with vasopressin cell antibodies. J Pediatr 1985;107:922–925.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.